HER2 Breast Cancer

Distinct gene signatures and BRCAness may correlate with pathologic complete response and invasive disease-free survival in patients with HER2-positive breast cancer treated with trastuzumab and pertuzumab with or without paclitaxel.

Treatment with neratinib demonstrated a modest overall survival benefit in patients with HER2-positive breast cancer compared with placebo, according to the long-term OS and central nervous system results from the phase 3 ExteNET trial.

Regardless of HER2 status, patients with human leukocyte antigen-A02, node-positive and high-risk node-negative breast cancer, had significant improvement in responses with a GP2 peptide vaccine plus GM-CSF compared with GM-CSF alone.

The experts describe the SOPHIA study of margetuximab in HER2+ advanced breast cancer.

Experts have a detailed conversation on the NALA trial of neratinib and capecitabine for HER2+ metastatic breast cancer.

Presentation and considerations for relapsed HER2+ metastatic breast cancer with progressing brain metastases.

In patients with breast cancer, who were predominantly hormone receptor–positive, 37.8% had a conversion to HER2-positive status that led to significant benefit from frontline treatment with taxane-trastuzumab with or without pertuzumab.

Sara A. Hurvitz, MD, discusses sequencing the current therapies for patients with HER2-positive breast cancer.

In the phase 2 MutHER study, the combination of neratinib and fulvestrant demonstrated activity in heavily pretreated patients with estrogen receptor-positive, metastatic breast cancer, but the clinical benefit rate did not meet the predefined efficacy criteria.

A panel of experts review the tucatinib regimen including adverse effects to keep an eye on.

Key opinion leaders consider later-lines of therapy in metastatic breast cancer with lung and brain involvement.

The experts discuss data from clinical trials of metastatic breast cancer with brain involvement.

The experts present and discuss a case of a patient with relapsed HER2+ metastatic breast cancer with stable brain metastases.

The panelists discuss clinical experience with the HER2CLIMB regimen, including main adverse effects.

The experts have a detailed conversation on the HER2CLIMB trial, including third-line treatment options and the importance of having a detailed and balanced conversation with patients.

Experts discuss the treatment considerations for HER2+ metastatic breast cancer and provide an overview of the DESTINY-Breast01 trial.

The experts discuss a case presentation of a 63-year-old woman with relapsed HER2+ metastatic breast cancer and discuss rate of relapse in this patient population.

Experts in breast cancer review clinical cases, discuss individualized treatment options and key clinical trials.

Debu Tripathy, MD, discusses the role that margetuximab will have in the field of HER2-positive metastatic breast cancer now that it is approved by the FDA.

In an interview with Targeted Oncology, Erika P. Hamilton, MD, explained how hormone receptor status in patients with HER2-positive breast cancer was affected by treatment with the HER2CLIMB regimen of tucatinib plus trastuzumab and capecitabine.

Positive efficacy and safety results observed with the proposed trastuzumab biosimilar, EG12014 in HER2-positive early breast cancer, has led the developer to plan regulatory filings in the United States, Europe, and China.

In an interview with Ecaterina Ileana Dumbrava, MD, discussed the ongoing study of BDC-1001 alone and in combination with an immune checkpoint inhibitor for the treatment of HER2-positive breast cancer and other solid tumors.

In an interview with Targeted Oncology, Joyce O’Shaughnessy, MD, chair of Breast Cancer Research and chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center of Texas Oncology, discussed the CONTESSA stusy of tesetaxel with a reduced dose of capecitabine versus capecitabine alone in patients with HR-positive, HER2-negative breast cancer.

Debu Tripathy, MD, discusses escalation and de-escalation of treatment in patients with HER2-positive breast cancer with HER2-targeted agents and chemotherapy.

Ecaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.

During a Targeted Oncology Case-Based Peer Perspectives event, Sara M. Tolaney, MD, MPH, discussed therapies available for the treatment of a 42-year-old woman with HER2-positive breast cancer.

Final analysis of data on HER2-positive disease presented at the 2020 San Antonio Breast Cancer Symposium from experts in the field of breast oncology.

Experts in breast oncology discuss the evolving role of trastuzumab deruxtecan for metastatic HER2-positive breast cancer.

Hatem Soliman, MD, reviews statistically significant data from the PERTAIN study, presented at the 2020 San Antonio Breast Cancer Symposium.

Experts in breast oncology discuss their real-world experience with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer.